GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

Segment wise Revenue, Results and Capital Employed, under Clause 41 of the Listing Agreement

(Rs. lakhs)

Unaudited			Unaudited		Audited
3 months	3 months		6 months	6 months	Year
ended	ended		ended	ended	ended
30.06.2007	30.06.2006		30.06.2007	30.06.2006	31.12.200
		Segment Revenue:			
37809	35943	a) Pharmaceuticals	77749	74008	14160
3343	5752	b) Other Businesses	6612	11074	1813
41152 -	41695	Total Segment Revenue	84361	85082	15973
	-	Less: Inter Segment Revenue	-	-	
41152	41695	Net Sales / Income from Operations	84361	85082	15973
		Segment Results (Profit before Interest and Tax):			
13609	12468	a) Pharmaceuticals	28957	26649	4921
660	1100	b) Other Businesses	1362	2050	384
14269	13568	Total Segment Results	30319	28699	5305
		Add/(Less):			
1056	705	(i) Interest Income (net)	2065	1493	342
(346)	(314)	(ii) Unallocable Income Net of Unallocable Expenditure	(546)	(276)	(89)
14979	13959	Total Profit Before Tax and Exceptional Items	31838	29916	5559
		Capital Employed (Segment Assets less Segment Liabilities):			
20630	17184	a) Pharmaceuticals	20630	17184	1584
6205	7758	b) Other Businesses	6205	7758	604
26835	24942	Total Capital Employed in Segments	26835	24942	2188

Notes:

- 1 Refer Notes 1 and 4 of the aforesaid unaudited financial results for the half year ended 30th June, 2007
- 2 (i) The Company is organised into two main business segments, namely:
 - Pharmaceuticals comprising of bulk drugs and formulations
 - Others primarily comprising of fine chemicals, diagnostics, laboratory equipment and exports mainly relating to pharmaceuticals. Animal Health business formed part of the Company's Other Businesses segment in the previous year.

Segments have been identified and reported taking into account, the nature of products and services, the differing risks and returns, the organisation structure, and the internal financial reporting systems.

- (ii) Segment Revenue in each of the above domestic business segments primarily includes sales (net of excise duty), processing charges, consignment sales commission, clinical research and data management and export incentives in the respective segments.
- (iii) Segment Revenue, Results, Assets and Liabilities include the respective amounts identifiable to each of the segments and amounts allocated on a reasonable basis.